Correspondence 0001178913-26-002074 from Evogene Ltd. (EVGN)
Evogene Ltd.
Date: April 13, 2026 · CIK: 0001574565 · Accession: 0001178913-26-002074
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294650
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Nicholas O’Leary Evogene Ltd. (the “Company”) Registration Statement on Form F-3 Filed March 26, 2026 File No. 333-294650
Dear Mr. O’Leary:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-294650) be accelerated by the Securities and Exchange Commission to 9:00 a.m., Eastern Daylight Time, on April 15, 2026 or as soon as possible thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness by email to Jonathan M. Nathan, Adv., of Meitar Law Offices, at jonathann@meitar.com. Please also contact Mr. Nathan if you have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely,
EVOGENE LTD.
Show Raw Text
CORRESP
1
filename1.htm
Evogene Ltd.
13 Gad Feinstein Street, Park Rehovot
Rehovot 7638517, Israel
April 13, 2026
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Nicholas O’Leary
Re:
Evogene Ltd. (the “Company”)
Registration Statement on Form F-3
Filed March 26, 2026
File No. 333-294650
Dear Mr. O’Leary:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the effective date of the Company’s Registration Statement on Form F-3 (File No. 333-294650) be accelerated by the
Securities and Exchange Commission to 9:00 a.m., Eastern Daylight Time, on April 15, 2026 or as soon as possible thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such
effectiveness by email to Jonathan M. Nathan, Adv., of Meitar Law Offices, at jonathann@meitar.com. Please also contact Mr. Nathan if you have any other questions or concerns regarding this matter.
[Signature page follows]
Sincerely,
EVOGENE LTD.
By:
/s/ Ofer Haviv
Name:
Ofer Haviv
Title:
Chief Executive Officer and President
cc:
Polina Ravzin, VP Finance, Evogene Ltd.
Howard E. Berkenblit, Esq.,
Sullivan & Worcester LLP
Brendan O’Brien, Esq.,
Sullivan & Worcester LLP
Mike Rimon, Adv., Meitar Law Offices
Jonathan M. Nathan, Adv., Meitar Law Offices
Elad Ziv, Adv., Meitar Law
Offices